As soon as Ariad announced the commercial availability of Ponatinib for adult patients with refractory chronic myeloid leukemia, global pharmaceutical players were all over it.
+------------------------------------------------------------------------------+
BN 03/28 14:32 *JENOPTIK SHARES RISE AFTER REPORT OF POTENTIAL THURINGIA PLANS BN 03/28 14:30 *THURINGIA MULLS BLOCKING MINORITY IN JENOPTIK: MANAGER MAGAZIN BN 03/28 14:29 *GERMAN STATE OF THURINGIA HAS 11% IN JENOPTIK: MANAGER MAGAZIN BN 03/28 14:28 *THURINGIA MULLS RAISING STAKE IN JENOPTIK, MANAGER MAGAZIN SAYS
+------------------------------------------------------------------------------+
*THURINGIA MULLS RAISING STAKE IN JENOPTIK, MANAGER MAGAZIN SAYS 2014-03-28 14:35:15.975 GMT
--BRIAN LYSAGHT
-0- Mar/28/2014 14:35 GMT
+------------------------------------------------------------------------------+
BN 03/28 12:50 *LIBERTY GLOBAL, ZIGGO SUPPLIERS QUIZZED BY EU ON TV MARKET
+------------------------------------------------------------------------------+
*LIBERTY GLOBAL, ZIGGO SUPPLIERS QUIZZED BY EU ON TV MARKET 2014-03-28 12:51:12.897 GMT
--JANET FREUND
-0- Mar/28/2014 12:51 GMT
Other news: INO -12.1% (pulling back), AT -6.9% (to sell US equity manager River Road to Affiliated Managers Group), ECYT -6.8% (prices 4.5 mln shares of its common stock at $21.00 per share), CZR -5.1% (announces offering of 7 mln shares of common stock), EXLP -4.8% (announces public offering of 5.4 mln common units representing limited partner interests), PUK -4.8% andLYG -3.1% (UK regulator to investigate 'fairness' of old savings products, according to reports), COMM -3% (prices secondary offering of 17.5 mln shares of its common stock by selling shareholders at $22.00 per share), ZGNX -2.7% (provides statement on Massachusetts denial of legitimate option for patients with severe chronic pain), NLY -2.5% (still checking), ONVO -1.7% (on VJET results), SFM -1.2% (prices 15 mln shares of common stock by selling shareholders at $33.75 per share), V -1% (Wal-Mart launching lawsuit over fees), GILD -0.9% (European Medicines Agency validates MAA for Ledipasvir/Sofosbuvir fixed-dose combination tablet for Genotype 1 chronic Hepatitis C infection ), NFLX -0.6% (AMZN plans to offer free service for streaming TV / music according to WSJ but recent reports inficate that AMZN denied the story), DDD -0.6% (on VJET results).
Analyst comments: PCG -5.4% (downgraded to Hold from Buy at Deutsche Bank; downgraded to Neutral from Buy at Citigroup), CIEN -1% (downgraded to Sector Perform at RBC Capital Mkts), JDSU -1% (downgraded to Sector Perform at RBC Capital Mkts)
M&A news: ARIA +6.8% ( DailyMail discusses rumors that Jazz may acquire ARIA for $20/share).
Select financial related names showing strength: RBS +1.2%, BAC +0.9%, DB +0.8%, BNS +0.7%.
Metals/mining stocks trading higher: MUX +9.3% , AUQ +3%, HMY +2.9%, KGC+2% (upgraded to Neutral from Sell at Goldman), BHP +1.6%, RIO +1.4%, GDX +1.2%, NEM +1.1%, BBL +0.9%, GLD +0.2%, AA +0.5% (upgraded to Neutral from Underperform at Macquarie; tgt raised to $10 from $5).
A few battery names are modestly higher: BLDP +2.7%, FCEL +2.5%, TSLA +0.2% (NJ sales ban has been delayed for 15 days, according to reports)
Other news: IDRA +31.2% (announces positive top-line data in Phase 2 Trial of IMO-8400; Trial meets primary objective of demonstrating safety and tolerability over 12-week treatment period; IMO-8400 also demonstrates clinical proof-of-concept in psoriasis), EXAS +9.1% (confirms FDA Advisory Committee unanimously recommends approval of Cologuard), ICLD +6.2% (refutes allegations made against the company; InterCloud remains focused on operations and growth), ZNGA +4.7% (S.A.C. Capital discloses 5.3% passive stake in 13G filing), HALO +3.7% (announces Roche Marketing Authorization For MabThera SC for patients with common forms of Non-Hodgkin Lymphoma In European Union), MPO +3% (S.A.C. Capital discloses 5.0% passive stake in 13G filing), MERC+2.1% (announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $7.15 per share), TNET +2.1% (continued strength following yesterday's IPO), SFXE +1.6% (following yesterday's earnings weakness; co commented on 2014 marketing and sponsorship EBITDA of over $40 Million), BUD +1.5% (still checking), BAX +1.4% (Barron's profiles positive view on Baxter), PRGX +1.2% (announces $10 mln increase in stock repurchase program), TWC +1.2% (checking for naything new; ongoing M&A speculation in cable/broadcasting names), AWR +1.1% (announces 1.25 mln share repurchase program), FEYE +0.9% (modestly rebounding; Reuters discusses comments from Google (GOOG) researchers that news firms may be under attack by hackers ), FB +0.9% (still checking), BIDU +0.9% (won lawsuit over search results censorship, according to reports ), AMZN +0.6% (has denied repots of free video streaming service, according to reports ), QDEL +0.5% (receives FDA Clearance for AmpliVue hand-held molecular diagnostic test for Herpes Simplex Virus Types 1 and 2).
Analyst comments: CTSH +4% (upgraded to Overweight from Equal Weight at Morgan Stanley ), SCTY +3.7% (upgraded to Outperform from Mkt Perform at Raymond James), SNN +1.8% (upgraded to Buy from Add at Investec), PFSI +1.2% (upgraded to Outperform from Market Perform at Wells Fargo), TEVA +1.1% (target raised to $60 from $56 at Citigroup; added to US Focus list),LULU +1% (upgraded to Outperform from Underperform at Credit Agricole; tgt raised to $60 from $54), AGN +0.7% (target raised to $140 from $130 at Citigroup), INVN +0.7% (upgraded to Buy from Neutral at ROTH Capital)